Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase II study from the North American Marrow Transplant Group

Donald R. Fleming, Steven N. Wolff, Joseph W. Fay, Randy A. Brown, Joseph P. Lynch, Brian J. Bolwell, Don A. Stevens, Stacy A. Goodman, John P. Greer, Richard S. Stein, Luis A. Pineiro, Robert H. Collins, Linda Jane Goldsmith, Geoffrey P. Herzig, Roger H. Herzig

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase II study from the North American Marrow Transplant Group'. Together they form a unique fingerprint.

Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: A phase II study from the North American Marrow Transplant Group

Fingerprint

Medicine & Life Sciences